The New Drug Application for viloxazine hydrochloride, a serotonin norepinephrine modulating agent, has been submitted to the FDA for the treatment of pediatric patients with ADHD.
The odds of receiving an ADHD diagnosis were increased with having an eating disorder, depressive disorder, bipolar disorder, or anxiety disorder.
Treatment with methylphenidate affects specific tracts in brain white matter in boys with attention-deficit/hyperactivity disorder.
Adhansia XR (methylphenidate HCl extended-release capsules) for the treatment of attention deficit hyperactivity disorder in patients aged 6 years and older, has launched.
Current guidelines include recommendations on how to prescribe methylphenidate, but lack of recommendations regarding the long-term use of the drug.
Adhansia XR (methylphenidate HCl extended-release capsules) is expected to be available as of July 15, 2019 for the treatment of attention deficit hyperactivity disorder (ADHD) in patients 6 years of age and older, according to Adlon Therapeutics.
Subtle differences in cortical surface area are widespread in children with attention-deficit/hyperactivity disorder, confirming involvement of the frontal cortex.
A higher omega-6 to omega-3 ratio in the mother’s diet may increase the risk of attention deficit hyperactivity disorder (ADHD) symptoms in offspring, according to findings from a study published in the Journal of Pediatrics. Researchers quantified the levels of omega-6 and -3 that reached the fetus by sampling umbilical cord plasma. Omega-3 and omega-6…
A recent study published in the New England Journal of Medicine assessed the risk of new-onset psychosis among adolescents and young adults with attention deficit hyperactivity disorder (ADHD) initiated on various stimulant medications.
Researchers sought to determine whether prenatal exposure to valproate and other antiepileptic drugs (AEDs) increases the risk for ADHD in offspring.